Get the Stockscreener App
7.88
1.87%
-0.15
After Hours:
7.88
Regenxbio Inc stock is traded at $7.88, with a volume of 1.12M.
It is down -1.87% in the last 24 hours and down -26.49% over the past month.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
See More
Previous Close:
$8.03
Open:
$8.24
24h Volume:
1.12M
Relative Volume:
0.59
Market Cap:
$520.18M
Revenue:
$170.44M
Net Income/Loss:
$-193.88M
P/E Ratio:
-2.099
EPS:
-3.7541
Net Cash Flow:
$-126.38M
1W Performance:
-9.32%
1M Performance:
-26.49%
6M Performance:
-2.72%
1Y Performance:
-11.36%
1-Day Range:
$7.76
$8.3132
1-Week Range:
$7.6359
$8.75
52-Week Range:
$5.455
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.88 | 563.09M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
510.72 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
798.17 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
172.94 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
988.20 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.67 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
Avoiding Lag: Real-Time Signals in (RGNX) Movement - Stock Traders Daily
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Wet Age-Related Macular Degeneration Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Opthea Limited, Regenxbio, Alkahest, Graybug Vision, Alcon Research - Barchart.com
REGENXBIO to present at two major healthcare investor conferences in September 2026 - Pluang
REGENXBIO to Participate in Upcoming Investor Conferences - marketscreener.com
This REGENXBIO Insider Increased Their Holding In The Last Year - 富途牛牛
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? - Stocktwits
RGNX Stock: Clear Street Sees Potential Cash Risk From RGX-121 FDA Hold - Stocktwits
Regenxbio Stock Price Forecast. Should You Buy RGNX? - StockInvest.us
REGENXBIO Inc. (RGNX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome - Yahoo Finance
REGENXBIO CTO Malzahn Craig Retains 81,960 Shares After Forfeiture on September 1, 2026 - Kalkine Media
REGENXBIO CFO Chan Mitchell Forfeits 4,902 Shares at $9.32 Each (NASDAQ: RGNX) - Kalkine Media
REGENXBIO CFO Mitchell Chan Reports Tax-Driven Share Withholding on RSU Vesting - Kalkine Media
How Regenxbio Inc. (RGNX) Affects Rotational Strategy Timing - Stock Traders Daily
REGENXBIO Faces Clinical Hold on RGX-121 but Duchenne BLA Advances - streetwisereports.com
REGENXBIO Faces FDA Clinical Hold on Hunter Syndrome Gene Therapy - Streetwise Reports
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
People on the Move: Greg Ciongoli Joins REGENXBIO’s Board of Directors - BioBuzz
Regenxbio stock surges on director share purchases By Investing.com - Investing.com Nigeria
Regenxbio stock surges on director share purchases - Investing.com
Why is Regenxbio stock rallying today? - investing.com
REGENXBIO : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
H.C. Wainwright cuts Regenxbio stock price target on clinical hold - investing.com
Regenxbio's FDA Hold Threatens Voucher Windfall, Analysts Slash Targets - finance.biggo.com
Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold - Sahm
REGENXBIO Adds Greg Ciongoli to Board Ahead of Commercial Expansion - citybiz
Regenxbio appoints Greg Ciongoli to board of directors - investing.com
REGENXBIO says FDA places RGX-121 on clinical hold; BLA resubmission not expected soon - TradingView
FDA places clinical hold on Regenxbio’s gene therapy for Hunter Syndrome - The Mighty 790 KFGO
Regenxbio halts BLA resubmission for Hunter syndrome therapy By Investing.com - Investing.com Nigeria
REGENXBIO stock tumbles after FDA clinical hold on MPS II therapy - Investing.com Nigeria
Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling - Barron's
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights - Eastern Progress
REGENXBIO (NASDAQ:RGNX) Trading Down 3.9%Should You Sell? - MarketBeat
RGNX Q2 2026 Earnings: Gene Therapy Developer Posts 626% EPS SurpriseEBITDA Analysis - Vinanet
Walleye Capital LLC Invests $2.44 Million in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Zacks Research - MarketBeat
Assenagon Asset Management S.A. Has $2.03 Million Position in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO (RGNX) Pulls Back 2.29% to $10.66 — Gene Therapy Play Tests Key SupportPCR Moving Average - Vinanet
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits
(RGNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
HC Wainwright Has Pessimistic View of REGENXBIO Q3 Earnings - MarketBeat
REGENXBIO’s Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade) (NASDAQ:RGNX) - Seeking Alpha
H.C. Wainwright lowers Regenxbio stock price target on equity offering By Investing.com - Investing.com UK
RGNX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright lowers Regenxbio stock price target on equity offering - Investing.com
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
Dimensional Fund Advisors LP Increases Stock Position in REGENXBIO Inc. $RGNX - MarketBeat
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regenxbio Inc Stock (RGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ciongoli Gregory Austin | Director |
Aug 26 '26 |
Buy |
9.14 |
49,196 |
449,706 |
64,628 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Option Exercise |
7.86 |
2,161 |
16,985 |
215,170 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Sale |
13.64 |
2,161 |
29,476 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
7.86 |
36,725 |
288,658 |
249,734 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Sale |
12.86 |
36,725 |
472,284 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jun 29 '26 |
Sale |
11.04 |
19,608 |
216,472 |
213,009 |
0.05%
1.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):